BeyondSpring downgraded by B of A Securities with a new price target
$BYSI
Biotechnology: Pharmaceutical Preparations
Health Care
B of A Securities downgraded BeyondSpring from Buy to Underperform and set a new price target of $5.00 from $45.00 previously